Odyssey Therapeutics, Inc. (ODTX) Financial Statement Analysis

Quick health check

For a retail investor taking a first glance at Odyssey Therapeutics, Inc., the most immediate question is whether the company is profitable right now. The simple answer is no. Over the latest annual period (FY 2025), the company brought in a negligible $2.98M in revenue while incurring a massive net loss of -$148.65M, translating to an earnings per share (EPS) of -$48.93. This lack of profitability is entirely expected for a clinical-stage immune and infection medicine developer, but it remains a stark reality. Second, we must look at whether the company is generating real cash. It is not; the operating cash flow (CFO) for the year was deeply negative at -$129.47M, meaning real dollars are flowing out the door to keep the lights on and the labs running. Third, we ask if the balance sheet is safe. Surprisingly, despite the massive losses, the balance sheet is currently highly fortified. The company holds $181.36M in cash and short-term investments against zero traditional long-term debt, giving it a robust liquidity cushion. Finally, looking for near-term stress in the last two quarters, the primary concern is the sheer velocity of the cash burn. While the balance sheet is safe today, burning over $129M a year means the company’s current cash pile gives it a runway of roughly 1.4 years, forcing a countdown clock that creates inherent stress for existing shareholders.

Income statement strength

When examining the income statement of a biopharma company like Odyssey, traditional metrics like gross margin take a backseat to operating expenses, particularly Research & Development (R&D). The company reported total revenue of $2.98M for FY 2025, a figure that actually declined by -33.45% from the prior period. Because this revenue likely stems from early-stage grants or minor collaboration milestones rather than commercial product sales, the gross profit of $2.98M is financially meaningless against the tidal wave of expenses. The true story of the income statement is found in the operating costs. Odyssey spent a towering $126.62M on R&D in the latest annual period, heavily overshadowing its Selling, General, and Administrative (SG&A) expenses of $37.52M. This brings total operating expenses to $160.09M and pushes operating income down to -$157.11M.

Across the last two quarters reported (Q4 2023 and Q4 2024), we can see this trend of heavy operating losses remains consistent, with quarterly operating income sitting at -$31.19M and -$37.50M, respectively. Profitability is not just absent; it is structurally impossible at this phase of the company's life cycle. The simple "so what" for investors is that Odyssey Therapeutics currently has absolutely zero pricing power or commercial margin quality. Its income statement is purely a reflection of its cost control—or lack thereof—as it aggressively spends capital to advance its unapproved immune therapies through expensive clinical trials.

"Are earnings real?"

In the corporate world, investors often worry that a company might use accounting tricks to make its net income look better than its actual cash flow. For Odyssey Therapeutics, the situation is flipped: we need to check if the massive accounting losses represent a true drain on the bank account. The answer is yes. The company reported a net income of -$148.65M in FY 2025, and its cash flow from operations (CFO) was -$129.47M. The CFO is slightly less negative than the net income primarily because of non-cash expenses that are added back. For instance, the company recorded $14.32M in stock-based compensation—meaning they paid employees in shares rather than cash—and $4.91M in depreciation and amortization.

Working capital movements also slightly softened the blow to the cash balance. Looking at the balance sheet, accounts payable increased by $2.06M, meaning the company held onto a bit of its cash by delaying payments to suppliers. However, accrued expenses decreased by -$4.15M, indicating the company settled some previously recorded bills. When we calculate Free Cash Flow (FCF) by taking the CFO (-$129.47M) and subtracting the minimal capital expenditures of -$1.23M, we get a deeply negative FCF of -$130.70M. Ultimately, these figures prove that the earnings deficit is very real. The losses on the income statement closely mirror the actual cash flying out of the company’s treasury to fund its research.

Balance sheet resilience

Given the heavy operational cash bleed, a company’s ability to handle shocks depends entirely on the resilience of its balance sheet. On this front, Odyssey Therapeutics is standing on very solid, albeit temporary, ground. Let us look at liquidity first. The company holds $41.69M in pure cash and equivalents, plus another $139.67M parked in short-term investments, bringing immediate liquid resources to $181.36M. When we compare this to total current liabilities of just $26.48M, the company boasts a pristine current ratio of 7.2. This means that for every dollar of bills due within the next twelve months, Odyssey has over seven dollars in liquid assets ready to deploy.

From a leverage standpoint, the company operates with extreme conservatism. Total long-term debt is recorded as data not provided or essentially zero, though they do carry $21.9M in long-term lease obligations for their facilities. Because there is no traditional bank debt, the debt-to-equity ratio sits at an incredibly low 0.13. Solvency, therefore, is not a question of meeting interest payments—since interest expense was practically non-existent at -$0.02M—but rather a question of timeline. The balance sheet must be classified as a watchlist today. While the asset base is theoretically safe and leverage is a non-issue, burning through over $130M a year means this beautiful balance sheet will rapidly deteriorate without external intervention.

Cash flow "engine"

Understanding how a company funds its daily operations is crucial, and Odyssey’s cash flow "engine" is entirely external. A healthy, mature business funds its growth organically through its CFO. Odyssey, with its CFO trending consistently negative across the last two quarters and the latest annual period, cannot do this. Its operations are a furnace, not an engine. The actual funding comes almost exclusively from financing activities. In FY 2025, the company generated a massive $215.65M in positive financing cash flow. This capital injection was achieved not by taking on debt, but by selling pieces of the company—specifically, net preferred stock issuance of $212.46M and common stock issuance of $3.19M.

Additionally, the company operates an "asset-light" model regarding physical infrastructure. Capital expenditures (Capex) were exceptionally low at just -$1.23M for the year. This implies that Odyssey is not building massive manufacturing plants; instead, its cash is overwhelmingly directed toward intellectual property, lab testing, and paying third-party clinical organizations. The crucial takeaway regarding sustainability is that cash generation is highly uneven and undependable organically. Odyssey relies completely on the capital markets remaining open and willing to fund its next phase of trials. If investor appetite for high-risk biotech dries up, the company's financial engine will stall immediately.

Shareholder payouts & capital allocation

When a company is losing over a hundred million dollars a year, the concept of shareholder payouts is fundamentally nonexistent. Odyssey Therapeutics does not pay a dividend, and rightfully so. Initiating a dividend while sporting a negative CFO and FCF would be financial malpractice, as every single cent must be conserved to advance the drug pipeline toward commercial viability. Since dividends are off the table, retail investors must focus intently on the other side of capital allocation: share count changes and equity dilution.

This is where the harshest reality of Odyssey’s financial strategy comes into focus. In the latest annual period, the company's shares outstanding experienced an explosive growth rate, marked as a 245.3% share change. The company’s buyback yield dilution is recorded at -267.45%. In simple terms, to raise the $215.65M in financing cash flow mentioned earlier, the company had to create and sell millions of brand-new shares. For existing retail investors, this means severe dilution. If you owned a slice of the Odyssey pie a year ago, the company essentially baked two more identical pies and sold them to institutional investors, dramatically shrinking the percentage of the total company that your single slice represents. This capital allocation strategy—relentlessly selling stock to build cash reserves—ensures the company's survival, but it mathematically suppresses per-share value unless the underlying drug pipeline achieves a monumental breakthrough.

Key red flags + key strengths

To frame the final investment decision, retail investors must weigh the extreme polarities of this company’s financial statements.

Strengths:

1. Exceptional Liquidity: A current ratio of 7.2 and total liquid reserves of $181.36M provide a heavy buffer against immediate bankruptcy.
2. Zero Traditional Leverage: With a debt-to-equity ratio of 0.13 and no major long-term debt reported, the company is totally insulated from the crushing pressures of high interest rates and mandatory principal repayments.

Red Flags:

1. Severe Cash Burn: An annual operating cash flow deficit of -$129.47M against a $181M cash pile means the runway is uncomfortably short, mathematically forcing the company to seek new funds within the next 12 to 18 months.
2. Massive Shareholder Dilution: A 245.3% increase in share count is heavily punitive to current retail investors, permanently reducing their proportional claim on any future profits.

Overall, the foundation looks risky because the pristine balance sheet is actively eroding at a rapid pace. While the lack of debt is comforting, the extreme reliance on dilutive equity financing to survive makes this a highly speculative financial profile where the clock is constantly ticking.